Efficacy and safety of antibody-drug conjugates in EGFR-mutant non-small cell lung cancer after tyrosine kinase inhibitor resistance: a systematic review and meta-analysis - Quiz - MDSpire

Efficacy and safety of antibody-drug conjugates in EGFR-mutant non-small cell lung cancer after tyrosine kinase inhibitor resistance: a systematic review and meta-analysis

  • By

  • Xiao Ma

  • Gaofeng Li

  • Heng Li

  • July 16, 2026

Share

Original Source(s)

Efficacy and safety of antibody-drug conjugates in EGFR-mutant non-small cell lung cancer after tyrosine kinase inhibitor resistance: a systematic review and meta-analysis

  • by Xiao Ma, Gaofeng Li, Heng Li

  • July 16, 2026

Related Content

Helicobacter pylori infection in gastric cancer patients in French Guiana: a hospital-based study (2018–2023)

Distribution and function of human long-lasting T cells in aging and non-small cell lung cancer

Immunological barriers and engineering strategies for CAR-T cell therapy in acute myeloid leukemia